High-throughput multiplexed autoantibody detection to screen type 1 diabetes and multiple autoimmune diseases simultaneously.

ABSTRACT:

Background

Islet autoantibodies (IAbs) are the most reliable biomarkers to assess risk of progression to clinical type 1 diabetes (T1D). There are four major biochemically defined IAbs currently used in clinical trials that are equally important for disease prediction. The current screening methods use a radio-binding assay (RBA) for single IAb measurement, which are laborious and inefficient for large-scale screening. More importantly, up to 40% of patients with T1D have other autoimmune conditions that can be identified through relevant autoantibody testing. Thus, there is a need to screen for T1D and other autoimmune diseases simultaneously.

Methods

Based on our well-established electrochemiluminescence (ECL) assay platform, we developed a multiplexed ECL assay that combi

SUBMITTER: Gu Y 

PROVIDER: S-EPMC6796526 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature